118:
17:
83:(VEGF), which is a strong vasodilator. VEGF has been indicated to stimulate sprouting and tip branching in endothelial cells, leading to defective endothelial monolayers. Research supports that compression of tumor vessels by surrounding tumor cells results in mechanical tension and changes in blood flow. It has been suggested that these flow-mediated changes cause abnormal expression of transcription factors which promotes aberrant endothelial morphology, size, and differentiation.
21:
18:
155:, or the process of forming new blood vessels, has been around since the discovery of VEGF in 1989. The branching patterning of tumor-associated endothelial cells has been implicated in the initiation of angiogenesis. Dr. Judah Folkman played an important role in studying the role of angiogenesis in promoting tumor growth. He identified tumor's response to hypoxia as a leading contributor to angiogenesis and cancer growth.
20:
1664:
Buckanovich, Ronald J.; Facciabene, Andrea; Kim, Sarah; Benencia, Fabian; Sasaroli, Dimitra; Balint, Klara; Katsaros, Dionysios; O'Brien-Jenkins, Anne; Gimotty, Phyllis A. (2008-01-01). "Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy".
90:
which help with vessel stability. Loss of pericyte growth factor (PDGFB) and its receptor on endothelial cells are molecular-level changes that can account for this abnormal loss in pericyte support. Lower quantity of pericytes surrounding the tumor-associated endothelium has been associated with
62:
without overlap, but TECs create disorganized and loosely connected monolayers, often branching and extending across the lumen to overlap with their neighbors. In addition to this, TECs are showing distinct molecular signature which clearly separates them from physiological endothelial cells. The
217:
by capturing cancer cells at their primary sites and providing for their delivery to secondary organs. These tumor-associated endothelial cells can also release factors and supply nutrients that promote the growth of the primary tumor mass and its aggressive spread. Additionally, angiogenesis is
162:
based on assumptions that the underlying processes were similar amongst different tumor types. However, there are now multiple studies that illustrate the complexity behind these previous simple conceptions of angiogenesis, indicating that the way cancer cells interact with and co-opt new blood
137:
and has been exploited for cancer nano-therapeutics. Unfortunately the effectiveness of this mechanism for drug nano-carriers remains inconsistent due to the heterogeneity of this EPR effect within and amongst different tumors. Tumor type, size, and location affect the nature of the surrounding
183:
and sutinib are additional angiogenesis inhibitors that bind and block receptors on endothelial cells that have important roles in downstream pathways contributing to angiogenesis progression. An extensive amount of other compounds targeted towards halting angiogenesis are either currently in
108:
often pool and form blood lakes. These cellular openings contribute to tumor vessel "leakiness", potentially allowing the entry and delivery of therapeutic agents to tumor sites. For many tumors, it has been discovered associated endothelial cells have significantly increased permeability.
196:
Immune therapies depend heavily on the abilities of effector lymphocytes to infiltrate tumors, and the tumor endothelium is a known crucial regulator of T-cell trafficking. The tumor-associated endothelium has been found to be able to function as an immune barrier to
19:
57:
Tumor endothelial cells (TECs) have been documented to demonstrate abnormal morphological characteristics such as ragged margins and irregular cytoplasmic projections. In normal blood vessels, it is known that endothelial cells form regular monolayers with
71:), supporting the existence of irregular gaps between endothelial cells. At a more macro level, beyond the observation of small intercellular openings between nearby TECs, larger gaps in the walls of tumor blood vessels have been described.
163:
vessel growth varies amongst cancer types and must be studied. This must be studied in order to improve clinical design strategy and select for patients with tumors that are more likely to benefit from anti-angiogenic drugs.
45:, gene expression, and functionality in ways that promote cancer progression. There has been notable interest in developing cancer therapeutics that capitalize on these abnormalities of the tumor-associated
40:
that control the passage of nutrients into surrounding tumor tissue. Across different cancer types, tumor-associated blood vessels have been discovered to differ significantly from normal blood vessels in
129:
to leave the blood system and directly enter the tumor interstitial space. There is also a retention effect that allows these macromolecules to stay at tumor sites due to the suppression of
1231:
Gerhardt, Holger; Golding, Matthew; Fruttiger, Marcus; Ruhrberg, Christiana; Lundkvist, Andrea; Abramsson, Alexandra; Jeltsch, Michael; Mitchell, Christopher; Alitalo, Kari (2003-06-23).
1131:
Prabhakar, Uma; Maeda, Hiroshi; Jain, Rakesh K.; Sevick-Muraca, Eva M.; Zamboni, William; Farokhzad, Omid C.; Barry, Simon T.; Gabizon, Alberto; Grodzinski, Piotr (2013-04-15).
525:
di Tomaso, Emmanuelle; Capen, Diane; Haskell, Amy; Hart, Janet; Logie, James J.; Jain, Rakesh K.; McDonald, Donald M.; Jones, Rosemary; Munn, Lance L. (2005-07-01).
424:
Lu, Chunhua; Bonome, Tomas; Li, Yang; Kamat, Aparna A.; Han, Liz Y.; Schmandt, Rosemarie; Coleman, Robert L.; Gershenson, David M.; Jaffe, Robert B. (2007-02-16).
468:
Hashizume, Hiroya; Baluk, Peter; Morikawa, Shunichi; McLean, John W.; Thurston, Gavin; Roberge, Sylvie; Jain, Rakesh K.; McDonald, Donald M. (2017-04-21).
1058:
Maeda, H; Wu, J; Sawa, T; Matsumura, Y; Hori, K (2000-03-01). "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review".
1093:
Iyer, Arun K.; Khaled, Greish; Fang, Jun; Maeda, Hiroshi (2006-09-01). "Exploiting the enhanced permeability and retention effect for tumor targeting".
330:
Milosevic, Vladan; Edelmann, Reidunn J.; Fosse, Johanna Hol; Ă–stman, Arne; Akslen, Lars A. (2022), Akslen, Lars A.; Watnick, Randolph S. (eds.),
1875:
Molecular
Phenotypes of Endothelial Cells in Malignant Tumors. In: Akslen, L.A., Watnick, R.S. (eds) Biomarkers of the Tumor Microenvironment
218:
intimately linked to metastasis, as delivery of nutrients and oxygen through blood vessels is required for invasive tumor growth and spread.
121:
Illustration of the
Enhanced Permeation and Retention (EPR) effect of macromolecular structures as drug delivery systems in malignant tissue.
134:
1133:"Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology"
831:
Baluk, Peter; Hashizume, Hiroya; McDonald, Donald M (2005-02-01). "Cellular abnormalities of blood vessels as targets in cancer".
201:, inhibiting the effectiveness of immune therapies. These tumor-associated endothelial cells have been found to over-express the
617:
Padera, Timothy P.; Stoll, Brian R.; Tooredman, Jessica B.; Capen, Diane; di Tomaso, Emmanuelle; Jain, Rakesh K. (2004-02-19).
351:
1564:
Shih, Ted; Lindley, Celeste (2006-11-01). "Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies".
426:"Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma"
574:
Nagy, Janice A.; Dvorak, Ann M.; Dvorak, Harold F. (2007-01-01). "VEGF-A and the induction of pathological angiogenesis".
917:"Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules"
80:
63:
tumor endothelium is often described as mosaic due to its aberrant expression of traditional endothelial cell markers (
1776:
Jahroudi, N.; Greenberger, J. S. (1995-01-01). "The role of endothelial cells in tumor invasion and metastasis".
1015:
Gerlowski, L. E.; Jain, R. K. (1986-05-01). "Microvascular permeability of normal and neoplastic tissues".
527:"Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers"
185:
774:
Hellström, M.; Gerhardt, H.; Kalén, M.; Li, X.; Eriksson, U.; Wolburg, H.; Betsholtz, C. (2001-04-30).
202:
171:
Various angiogenesis inhibitors have been developed to interfere with different steps in the process.
1356:
184:
preclinical development, undergoing clinical trials, or in the process of getting approved by the
104:
Where these branched tumor-associated endothelial cells form small gaps in the blood vessel wall,
159:
117:
1874:
1291:
Zetter, Bruce R. (2008). "The scientific contributions of M. Judah
Folkman to cancer research".
179:) is a monoclonal antibody that binds to VEGF, preventing the stimulation of the VEGF receptor.
1351:
227:
630:
587:
42:
1716:
Kandalaft, Lana E.; Facciabene, Andrea; Buckanovich, Ron J.; Coukos, George (2009-07-15).
1342:
Folkman, J. (1990-01-03). "What is the evidence that tumors are angiogenesis dependent?".
8:
776:"Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis"
634:
1809:
1750:
1717:
1698:
1641:
1608:
1541:
1508:
1481:
1448:
1324:
1265:
1232:
1213:
1165:
1132:
997:
941:
916:
892:
867:
808:
775:
708:
675:
502:
469:
401:
376:
296:
263:
1840:
1071:
485:
392:
1852:
1844:
1801:
1793:
1755:
1737:
1690:
1682:
1646:
1628:
1589:
1581:
1546:
1528:
1486:
1468:
1426:
1418:
1377:
1369:
1316:
1308:
1270:
1252:
1205:
1170:
1152:
1110:
1075:
1040:
1032:
1028:
989:
981:
946:
928:
897:
879:
848:
813:
795:
756:
748:
744:
713:
695:
656:
648:
599:
591:
556:
548:
507:
489:
447:
406:
347:
301:
283:
1827:
Folkman, Judah (2002-12-16). "Role of angiogenesis in tumor growth and metastasis".
1813:
1702:
1577:
1217:
1001:
205:, which suppresses T-cell adhesion and targeting to tumors upon activation by ET-1.
1836:
1785:
1745:
1729:
1674:
1636:
1620:
1573:
1536:
1520:
1476:
1460:
1408:
1361:
1328:
1300:
1260:
1244:
1197:
1160:
1144:
1102:
1067:
1024:
973:
936:
887:
840:
803:
787:
740:
703:
687:
638:
583:
538:
497:
481:
437:
396:
388:
339:
291:
275:
1733:
1148:
731:
Hirschi, K. K.; D'Amore, P. A. (1996-10-01). "Pericytes in the microvasculature".
543:
526:
442:
425:
1893:
1106:
691:
1609:"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?"
1464:
343:
279:
1413:
1396:
105:
59:
1878:
1873:
Milosevic, V., Edelmann, R.J., Fosse, J.H., Ă–stman, A., Akslen, L.A. (2022).
1624:
1201:
844:
331:
1887:
1848:
1797:
1741:
1686:
1632:
1585:
1532:
1472:
1422:
1373:
1312:
1256:
1209:
1156:
1036:
985:
964:
Jain, R. K. (1987-01-01). "Transport of molecules across tumor vasculature".
932:
883:
799:
752:
699:
652:
595:
552:
493:
470:"Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness"
377:"Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness"
287:
126:
1856:
1759:
1694:
1650:
1593:
1550:
1490:
1430:
1320:
1274:
1233:"VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia"
1174:
1114:
1079:
852:
817:
717:
660:
603:
560:
511:
451:
410:
305:
232:
152:
138:
vasculature and stroma and contribute to this heterogeneity in EPR effect.
37:
1805:
1381:
1365:
1248:
1044:
993:
950:
791:
760:
901:
237:
172:
125:
The increased permeability of tumor-associated endothelial cells permits
46:
1789:
1524:
977:
915:
Dvorak, H. F.; Nagy, J. A.; Dvorak, J. T.; Dvorak, A. M. (1988-10-01).
866:
Van den Brenk, H. A.; Crowe, M.; Kelly, H.; Stone, M. G. (1977-04-01).
214:
180:
130:
25:
A visualization of tumor-associated blood vessels in the human breast
1715:
1304:
643:
618:
1678:
112:
87:
68:
1509:"Angiogenesis inhibitors: current strategies and future prospects"
1447:
Pezzella, F; Harris, A L; Tavassoli, M; Gatter, K C (2015-12-21).
176:
1663:
1230:
1188:
Hall, A. P. (2005-03-01). "The role of angiogenesis in cancer".
1130:
375:
Hashizume, H; Baluk, P; Morikawa, S; et al. (April 2000).
332:"Molecular Phenotypes of Endothelial Cells in Malignant Tumors"
198:
1718:"Endothelin B Receptor, a New Target in Cancer Immune Therapy"
1446:
868:"The significance of free blood in liquid and solid tumours"
865:
467:
329:
1449:"Blood vessels and cancer much more than just angiogenesis"
338:, Cham: Springer International Publishing, pp. 31–52,
64:
676:"Transcriptional control of endothelial cell development"
616:
524:
773:
86:
Smaller capillaries are often surrounded by supporting
914:
830:
619:"Pathology: cancer cells compress intratumour vessels"
374:
1607:
Gotink, Kristy J.; Verheul, Henk M. W. (2010-03-01).
1395:
Hanahan, Douglas; Weinberg, Robert A. (2011-03-04).
1057:
79:
Many tumors are characterized by high expression of
1775:
1092:
133:infiltration. This observation has been termed the
36:(TECs) refers to cells lining the tumor-associated
1507:Cook, Kristina M.; Figg, William D. (2010-07-01).
730:
1885:
573:
135:enhanced permeability and retention (EPR) effect
113:Enhanced permeability and retention (EPR) effect
1394:
423:
1606:
1014:
833:Current Opinion in Genetics & Development
674:De Val, Sarah; Black, Brian L. (2009-02-01).
141:
158:Angiogenesis was originally introduced as a
1879:https://doi.org/10.1007/978-3-030-98950-7_3
1563:
673:
268:Cold Spring Harbor Perspectives in Medicine
1397:"Hallmarks of Cancer: The Next Generation"
186:United States Food and Drug Administration
166:
74:
1749:
1640:
1540:
1480:
1412:
1355:
1264:
1164:
940:
891:
872:British Journal of Experimental Pathology
807:
707:
642:
542:
501:
441:
400:
295:
99:
1506:
1344:Journal of the National Cancer Institute
336:Biomarkers of the Tumor Microenvironment
116:
91:blood vessel instability and leakiness.
1826:
1341:
1886:
1290:
588:10.1146/annurev.pathol.2.010506.134925
261:
52:
1771:
1769:
1502:
1500:
1442:
1440:
1286:
1284:
1126:
1124:
191:
1187:
963:
835:. Oncogenes and cell proliferation.
463:
461:
370:
368:
325:
323:
321:
319:
317:
315:
257:
255:
253:
94:
1513:CA: A Cancer Journal for Clinicians
13:
1867:
1766:
1497:
1437:
1281:
1121:
81:vascular endothelial growth factor
30:Tumor-associated endothelial cells
15:
14:
1905:
921:The American Journal of Pathology
474:The American Journal of Pathology
458:
365:
312:
250:
262:Dudley, Andrew C. (2012-03-01).
1820:
1709:
1657:
1600:
1578:10.1016/j.clinthera.2006.11.015
1557:
1388:
1335:
1224:
1181:
1086:
1051:
1008:
957:
908:
859:
824:
767:
724:
146:
1190:Comparative Clinical Pathology
667:
610:
567:
518:
417:
1:
1841:10.1016/S0093-7754(02)70065-1
1734:10.1158/1078-0432.CCR-08-0543
1149:10.1158/0008-5472.CAN-12-4561
1072:10.1016/S0168-3659(99)00248-5
1060:Journal of Controlled Release
966:Cancer and Metastasis Reviews
544:10.1158/0008-5472.CAN-04-4552
486:10.1016/S0002-9440(10)65006-7
443:10.1158/0008-5472.can-06-3700
393:10.1016/S0002-9440(10)65006-7
243:
208:
151:The idea of tumors promoting
1107:10.1016/j.drudis.2006.07.005
1029:10.1016/0026-2862(86)90018-x
745:10.1016/0008-6363(96)00063-6
692:10.1016/j.devcel.2009.01.014
213:The vasculature can promote
7:
1465:10.1038/cddiscovery.2015.64
1237:The Journal of Cell Biology
780:The Journal of Cell Biology
344:10.1007/978-3-030-98950-7_3
280:10.1101/cshperspect.a006536
221:
10:
1910:
1414:10.1016/j.cell.2011.02.013
576:Annual Review of Pathology
142:Roles in tumor progression
1778:Journal of Neuro-Oncology
1625:10.1007/s10456-009-9160-6
1202:10.1007/s00580-004-0533-3
845:10.1016/j.gde.2004.12.005
264:"Tumor Endothelial Cells"
1722:Clinical Cancer Research
733:Cardiovascular Research
167:Angiogenesis inhibitors
75:Causes of abnormalities
34:tumor endothelial cells
1293:Nature Reviews. Cancer
1017:Microvascular Research
228:Tumor microenvironment
122:
100:Blood vessel leakiness
26:
1566:Clinical Therapeutics
1249:10.1083/jcb.200302047
792:10.1083/jcb.153.3.543
203:endothelin B receptor
120:
24:
1829:Seminars in Oncology
1453:Cell Death Discovery
1095:Drug Discovery Today
1366:10.1093/jnci/82.1.4
635:2004Natur.427..695P
53:Abnormal morphology
49:to destroy tumors.
1877:. Springer, Cham.
1790:10.1007/bf01053415
1525:10.3322/caac.20075
1101:(17–18): 812–818.
978:10.1007/bf00047468
680:Developmental Cell
192:Immune suppression
160:Hallmark of Cancer
123:
27:
1728:(14): 4521–4528.
1572:(11): 1779–1802.
537:(13): 5740–5749.
353:978-3-030-98950-7
95:Abnormal function
22:
1901:
1861:
1860:
1824:
1818:
1817:
1773:
1764:
1763:
1753:
1713:
1707:
1706:
1661:
1655:
1654:
1644:
1604:
1598:
1597:
1561:
1555:
1554:
1544:
1504:
1495:
1494:
1484:
1444:
1435:
1434:
1416:
1392:
1386:
1385:
1359:
1339:
1333:
1332:
1288:
1279:
1278:
1268:
1243:(6): 1163–1177.
1228:
1222:
1221:
1185:
1179:
1178:
1168:
1143:(8): 2412–2417.
1128:
1119:
1118:
1090:
1084:
1083:
1066:(1–2): 271–284.
1055:
1049:
1048:
1012:
1006:
1005:
961:
955:
954:
944:
912:
906:
905:
895:
863:
857:
856:
828:
822:
821:
811:
771:
765:
764:
728:
722:
721:
711:
671:
665:
664:
646:
614:
608:
607:
571:
565:
564:
546:
522:
516:
515:
505:
480:(4): 1363–1380.
465:
456:
455:
445:
436:(4): 1757–1768.
421:
415:
414:
404:
372:
363:
362:
361:
360:
327:
310:
309:
299:
259:
23:
1909:
1908:
1904:
1903:
1902:
1900:
1899:
1898:
1884:
1883:
1870:
1868:Further reading
1865:
1864:
1825:
1821:
1774:
1767:
1714:
1710:
1667:Nature Medicine
1662:
1658:
1605:
1601:
1562:
1558:
1505:
1498:
1445:
1438:
1393:
1389:
1357:10.1.1.599.5748
1340:
1336:
1305:10.1038/nrc2458
1289:
1282:
1229:
1225:
1186:
1182:
1137:Cancer Research
1129:
1122:
1091:
1087:
1056:
1052:
1013:
1009:
962:
958:
913:
909:
864:
860:
829:
825:
772:
768:
729:
725:
672:
668:
644:10.1038/427695a
615:
611:
572:
568:
531:Cancer Research
523:
519:
466:
459:
430:Cancer Research
422:
418:
373:
366:
358:
356:
354:
328:
313:
260:
251:
246:
224:
211:
194:
169:
149:
144:
115:
102:
97:
77:
60:tight junctions
55:
16:
12:
11:
5:
1907:
1897:
1896:
1882:
1881:
1869:
1866:
1863:
1862:
1819:
1765:
1708:
1679:10.1038/nm1699
1656:
1599:
1556:
1519:(4): 222–243.
1496:
1436:
1407:(5): 646–674.
1387:
1334:
1299:(8): 647–654.
1280:
1223:
1180:
1120:
1085:
1050:
1023:(3): 288–305.
1007:
972:(4): 559–593.
956:
907:
878:(2): 147–159.
858:
839:(1): 102–111.
823:
786:(3): 543–553.
766:
739:(4): 687–698.
723:
686:(2): 180–195.
666:
609:
566:
517:
457:
416:
387:(4): 1363–80.
364:
352:
311:
274:(3): a006536.
248:
247:
245:
242:
241:
240:
235:
230:
223:
220:
210:
207:
193:
190:
168:
165:
148:
145:
143:
140:
127:macromolecules
114:
111:
101:
98:
96:
93:
76:
73:
54:
51:
9:
6:
4:
3:
2:
1906:
1895:
1892:
1891:
1889:
1880:
1876:
1872:
1871:
1858:
1854:
1850:
1846:
1842:
1838:
1834:
1830:
1823:
1815:
1811:
1807:
1803:
1799:
1795:
1791:
1787:
1784:(2): 99–108.
1783:
1779:
1772:
1770:
1761:
1757:
1752:
1747:
1743:
1739:
1735:
1731:
1727:
1723:
1719:
1712:
1704:
1700:
1696:
1692:
1688:
1684:
1680:
1676:
1672:
1668:
1660:
1652:
1648:
1643:
1638:
1634:
1630:
1626:
1622:
1618:
1614:
1610:
1603:
1595:
1591:
1587:
1583:
1579:
1575:
1571:
1567:
1560:
1552:
1548:
1543:
1538:
1534:
1530:
1526:
1522:
1518:
1514:
1510:
1503:
1501:
1492:
1488:
1483:
1478:
1474:
1470:
1466:
1462:
1458:
1454:
1450:
1443:
1441:
1432:
1428:
1424:
1420:
1415:
1410:
1406:
1402:
1398:
1391:
1383:
1379:
1375:
1371:
1367:
1363:
1358:
1353:
1349:
1345:
1338:
1330:
1326:
1322:
1318:
1314:
1310:
1306:
1302:
1298:
1294:
1287:
1285:
1276:
1272:
1267:
1262:
1258:
1254:
1250:
1246:
1242:
1238:
1234:
1227:
1219:
1215:
1211:
1207:
1203:
1199:
1195:
1191:
1184:
1176:
1172:
1167:
1162:
1158:
1154:
1150:
1146:
1142:
1138:
1134:
1127:
1125:
1116:
1112:
1108:
1104:
1100:
1096:
1089:
1081:
1077:
1073:
1069:
1065:
1061:
1054:
1046:
1042:
1038:
1034:
1030:
1026:
1022:
1018:
1011:
1003:
999:
995:
991:
987:
983:
979:
975:
971:
967:
960:
952:
948:
943:
938:
934:
930:
927:(1): 95–109.
926:
922:
918:
911:
903:
899:
894:
889:
885:
881:
877:
873:
869:
862:
854:
850:
846:
842:
838:
834:
827:
819:
815:
810:
805:
801:
797:
793:
789:
785:
781:
777:
770:
762:
758:
754:
750:
746:
742:
738:
734:
727:
719:
715:
710:
705:
701:
697:
693:
689:
685:
681:
677:
670:
662:
658:
654:
650:
645:
640:
636:
632:
629:(6976): 695.
628:
624:
620:
613:
605:
601:
597:
593:
589:
585:
581:
577:
570:
562:
558:
554:
550:
545:
540:
536:
532:
528:
521:
513:
509:
504:
499:
495:
491:
487:
483:
479:
475:
471:
464:
462:
453:
449:
444:
439:
435:
431:
427:
420:
412:
408:
403:
398:
394:
390:
386:
382:
381:Am. J. Pathol
378:
371:
369:
355:
349:
345:
341:
337:
333:
326:
324:
322:
320:
318:
316:
307:
303:
298:
293:
289:
285:
281:
277:
273:
269:
265:
258:
256:
254:
249:
239:
236:
234:
231:
229:
226:
225:
219:
216:
206:
204:
200:
189:
187:
182:
178:
174:
164:
161:
156:
154:
139:
136:
132:
128:
119:
110:
107:
92:
89:
84:
82:
72:
70:
66:
61:
50:
48:
44:
39:
38:blood vessels
35:
31:
1835:(6): 15–18.
1832:
1828:
1822:
1781:
1777:
1725:
1721:
1711:
1673:(1): 28–36.
1670:
1666:
1659:
1616:
1613:Angiogenesis
1612:
1602:
1569:
1565:
1559:
1516:
1512:
1456:
1452:
1404:
1400:
1390:
1347:
1343:
1337:
1296:
1292:
1240:
1236:
1226:
1196:(3): 95–99.
1193:
1189:
1183:
1140:
1136:
1098:
1094:
1088:
1063:
1059:
1053:
1020:
1016:
1010:
969:
965:
959:
924:
920:
910:
875:
871:
861:
836:
832:
826:
783:
779:
769:
736:
732:
726:
683:
679:
669:
626:
622:
612:
579:
575:
569:
534:
530:
520:
477:
473:
433:
429:
419:
384:
380:
357:, retrieved
335:
271:
267:
233:Angiogenesis
212:
195:
170:
157:
153:angiogenesis
150:
147:Angiogenesis
124:
106:erythrocytes
103:
85:
78:
56:
33:
29:
28:
1619:(1): 1–14.
582:: 251–275.
238:Endothelium
173:Bevacizumab
47:endothelium
1350:(1): 4–6.
359:2022-07-13
244:References
215:metastasis
209:Metastasis
43:morphology
1849:0093-7754
1798:0167-594X
1742:1078-0432
1687:1078-8956
1633:1573-7209
1586:0149-2918
1533:1542-4863
1473:2058-7716
1459:: 15064.
1423:0092-8674
1374:0027-8874
1352:CiteSeerX
1313:1474-1768
1257:0021-9525
1210:1618-5641
1157:0008-5472
1037:0026-2862
986:0167-7659
933:0002-9440
884:0007-1021
800:0021-9525
753:0008-6363
700:1878-1551
653:1476-4687
596:1553-4006
553:0008-5472
494:0002-9440
288:2157-1422
181:Sorafenib
131:lymphatic
88:pericytes
1888:Category
1857:12516034
1814:24723243
1760:19567593
1703:14822376
1695:18157142
1651:20012482
1594:17212999
1551:20554717
1491:27551488
1431:21376230
1321:18633354
1275:12810700
1218:31476527
1175:23423979
1115:16935749
1080:10699287
1002:20519826
853:15661540
818:11331305
718:19217421
661:14973470
604:18039100
561:15994949
512:10751361
452:17308118
411:10751361
306:22393533
222:See also
1806:7543941
1751:2896814
1642:2845892
1542:2919227
1482:4979496
1382:1688381
1329:8649851
1266:2172999
1166:3916009
1045:2423854
994:3327633
951:2459969
942:1880651
893:2041288
809:2190573
761:8915187
709:2728550
631:Bibcode
503:1876882
402:1876882
297:3282494
199:T-cells
177:Avastin
1894:Cancer
1855:
1847:
1812:
1804:
1796:
1758:
1748:
1740:
1701:
1693:
1685:
1649:
1639:
1631:
1592:
1584:
1549:
1539:
1531:
1489:
1479:
1471:
1429:
1421:
1380:
1372:
1354:
1327:
1319:
1311:
1273:
1263:
1255:
1216:
1208:
1173:
1163:
1155:
1113:
1078:
1043:
1035:
1000:
992:
984:
949:
939:
931:
902:861165
900:
890:
882:
851:
816:
806:
798:
759:
751:
716:
706:
698:
659:
651:
623:Nature
602:
594:
559:
551:
510:
500:
492:
450:
409:
399:
350:
304:
294:
286:
1810:S2CID
1699:S2CID
1325:S2CID
1214:S2CID
998:S2CID
69:CD105
1853:PMID
1845:ISSN
1802:PMID
1794:ISSN
1756:PMID
1738:ISSN
1691:PMID
1683:ISSN
1647:PMID
1629:ISSN
1590:PMID
1582:ISSN
1547:PMID
1529:ISSN
1487:PMID
1469:ISSN
1427:PMID
1419:ISSN
1401:Cell
1378:PMID
1370:ISSN
1317:PMID
1309:ISSN
1271:PMID
1253:ISSN
1206:ISSN
1171:PMID
1153:ISSN
1111:PMID
1076:PMID
1041:PMID
1033:ISSN
990:PMID
982:ISSN
947:PMID
929:ISSN
898:PMID
880:ISSN
849:PMID
814:PMID
796:ISSN
757:PMID
749:ISSN
714:PMID
696:ISSN
657:PMID
649:ISSN
600:PMID
592:ISSN
557:PMID
549:ISSN
508:PMID
490:ISSN
448:PMID
407:PMID
348:ISBN
302:PMID
284:ISSN
67:and
65:CD31
1837:doi
1786:doi
1746:PMC
1730:doi
1675:doi
1637:PMC
1621:doi
1574:doi
1537:PMC
1521:doi
1477:PMC
1461:doi
1409:doi
1405:144
1362:doi
1301:doi
1261:PMC
1245:doi
1241:161
1198:doi
1161:PMC
1145:doi
1103:doi
1068:doi
1025:doi
974:doi
937:PMC
925:133
888:PMC
841:doi
804:PMC
788:doi
784:153
741:doi
704:PMC
688:doi
639:doi
627:427
584:doi
539:doi
498:PMC
482:doi
478:156
438:doi
397:PMC
389:doi
385:156
340:doi
292:PMC
276:doi
32:or
1890::
1851:.
1843:.
1833:29
1831:.
1808:.
1800:.
1792:.
1782:23
1780:.
1768:^
1754:.
1744:.
1736:.
1726:15
1724:.
1720:.
1697:.
1689:.
1681:.
1671:14
1669:.
1645:.
1635:.
1627:.
1617:13
1615:.
1611:.
1588:.
1580:.
1570:28
1568:.
1545:.
1535:.
1527:.
1517:60
1515:.
1511:.
1499:^
1485:.
1475:.
1467:.
1455:.
1451:.
1439:^
1425:.
1417:.
1403:.
1399:.
1376:.
1368:.
1360:.
1348:82
1346:.
1323:.
1315:.
1307:.
1295:.
1283:^
1269:.
1259:.
1251:.
1239:.
1235:.
1212:.
1204:.
1194:13
1192:.
1169:.
1159:.
1151:.
1141:73
1139:.
1135:.
1123:^
1109:.
1099:11
1097:.
1074:.
1064:65
1062:.
1039:.
1031:.
1021:31
1019:.
996:.
988:.
980:.
968:.
945:.
935:.
923:.
919:.
896:.
886:.
876:58
874:.
870:.
847:.
837:15
812:.
802:.
794:.
782:.
778:.
755:.
747:.
737:32
735:.
712:.
702:.
694:.
684:16
682:.
678:.
655:.
647:.
637:.
625:.
621:.
598:.
590:.
578:.
555:.
547:.
535:65
533:.
529:.
506:.
496:.
488:.
476:.
472:.
460:^
446:.
434:67
432:.
428:.
405:.
395:.
383:.
379:.
367:^
346:,
334:,
314:^
300:.
290:.
282:.
270:.
266:.
252:^
188:.
1859:.
1839::
1816:.
1788::
1762:.
1732::
1705:.
1677::
1653:.
1623::
1596:.
1576::
1553:.
1523::
1493:.
1463::
1457:1
1433:.
1411::
1384:.
1364::
1331:.
1303::
1297:8
1277:.
1247::
1220:.
1200::
1177:.
1147::
1117:.
1105::
1082:.
1070::
1047:.
1027::
1004:.
976::
970:6
953:.
904:.
855:.
843::
820:.
790::
763:.
743::
720:.
690::
663:.
641::
633::
606:.
586::
580:2
563:.
541::
514:.
484::
454:.
440::
413:.
391::
342::
308:.
278::
272:2
175:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
_effect.svg)